These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32605977)

  • 1. Glucocorticoid-induced osteoporosis: Insights for the clinician.
    Hayat S; Magrey MN
    Cleve Clin J Med; 2020 Jun; 87(7):417-426. PubMed ID: 32605977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucocorticoid-induced osteoporosis: is the bone density decrease the only explanation?
    Lespessailles E; Poupon S; Adriambelosoa N; Pothuaud L; Siroux V; Bouillon S; Benhamou CL
    Joint Bone Spine; 2000; 67(2):119-26. PubMed ID: 10769104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [An update on glucocorticoid-induced osteoporosis].
    Krasselt M; Baerwald C
    Dtsch Med Wochenschr; 2016 Mar; 141(5):352-7. PubMed ID: 26939107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trabecular Bone Score in Patients With Chronic Glucocorticoid Therapy-Induced Osteoporosis Treated With Alendronate or Teriparatide.
    Saag KG; Agnusdei D; Hans D; Kohlmeier LA; Krohn KD; Leib ES; MacLaughlin EJ; Alam J; Simonelli C; Taylor KA; Marcus R
    Arthritis Rheumatol; 2016 Sep; 68(9):2122-8. PubMed ID: 27111239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A histomorphometric long-term longitudinal study of trabecular bone loss in glucocorticoid-treated patients: prednisone versus deflazacort.
    LoCascio V; Ballanti P; Milani S; Bertoldo F; LoCascio C; Zanolin EM; Bonucci E
    Calcif Tissue Int; 1998 Mar; 62(3):199-204. PubMed ID: 9501951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Time of Administration of Teriparatide on Bone Mineral Density in Glucocorticoid-Induced Osteoporosis.
    Mastaglia SR
    J Clin Densitom; 2017; 20(4):513-515. PubMed ID: 28579148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of multiple vertebral compression fractures due to glucocorticoid-induced osteoporosis in a pediatric patient with nephrotic syndrome
.
    Ashida A; Fujii Y; Matsumura H; Tamai H
    Int J Clin Pharmacol Ther; 2017 Mar; 55(3):264-269. PubMed ID: 27936525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of recency and duration of glucocorticoid use on bone mineral density and risk of fractures.
    de Villiers TJ
    Climacteric; 2014 Feb; 17(1):101. PubMed ID: 24571030
    [No Abstract]   [Full Text] [Related]  

  • 9. Glucocorticoid-Induced Osteoporosis: Why Kids Are Different.
    Ward LM
    Front Endocrinol (Lausanne); 2020; 11():576. PubMed ID: 33391179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials.
    Amiche MA; Albaum JM; Tadrous M; Pechlivanoglou P; Lévesque LE; Adachi JD; Cadarette SM
    Osteoporos Int; 2016 May; 27(5):1709-18. PubMed ID: 26694595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study.
    Emkey R; Delmas PD; Goemaere S; Liberman UA; Poubelle PE; Daifotis AG; Verbruggen N; Lombardi A; Czachur M
    Arthritis Rheum; 2003 Apr; 48(4):1102-8. PubMed ID: 12687554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effects of glucocorticoid on bone architecture and strength].
    Soen S
    Clin Calcium; 2013 Jul; 23(7):993-9. PubMed ID: 23811587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Glucocorticosteroid induced osteoporosis in patients with rheumatoid arthritis].
    Leszczyński P; Lacki JK; Mackiewicz SH
    Przegl Lek; 2000; 57(2):108-10. PubMed ID: 10907353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options.
    De Nijs RN
    Minerva Med; 2008 Feb; 99(1):23-43. PubMed ID: 18299694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The disconnect between better quality of glucocorticoid-induced osteoporosis preventive care and better outcomes: a population-based cohort study.
    Majumdar SR; Lix LM; Morin SN; Yogendran M; Metge CJ; Leslie WD
    J Rheumatol; 2013 Oct; 40(10):1736-41. PubMed ID: 23818715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Systemic Glucocorticoid Use on Fracture Risk: A Population-Based Study.
    Koh JW; Kim J; Cho H; Ha YC; Kim TY; Lee YK; Kim HY; Jang S
    Endocrinol Metab (Seoul); 2020 Sep; 35(3):562-570. PubMed ID: 32981298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucocorticoid-induced osteoporosis: pathogenesis, diagnosis, and management.
    McIlwain HH
    Prev Med; 2003 Feb; 36(2):243-9. PubMed ID: 12591000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucocorticoid-induced osteoporosis.
    Compston J
    Horm Res; 2003; 60 Suppl 3():77-9. PubMed ID: 14671402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trabecular Bone Score Reflects Trabecular Microarchitecture Deterioration and Fragility Fracture in Female Adult Patients Receiving Glucocorticoid Therapy: A Pre-Post Controlled Study.
    Chuang MH; Chuang TL; Koo M; Wang YF
    Biomed Res Int; 2017; 2017():4210217. PubMed ID: 28127556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of glucocorticoid-induced osteoporosis.
    Messina OD; Vidal LF; Wilman MV; Bultink IEM; Raterman HG; Lems W
    Aging Clin Exp Res; 2021 Apr; 33(4):793-804. PubMed ID: 33751462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.